p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features

Japanese Journal of Clinical Oncology

Volumn 41, Issue 2, 2011, Pages 172-179

  Biganzoli, Elia ^a,b   Coradini, Danila ^a   Ambrogi, Federico ^a   Garibaldi, Jonhatan M ^c   Lisboa, Paulo ^d   Soria, Daniele ^c   Green, Andrew R ^e   Pedriali, Massimo ^f   Piantelli, Mauro ^g   Querzoli, Patrizia ^f   Demicheli, Romano ^b   Boracchi, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f UNIVERSITY OF FERRARA   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biological marker; Breast cancer; Prognosis; Triple negative

Indexed keywords

ACTIN; ANDROGEN RECEPTOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CHROMOGRANIN A; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; GCDFP 15 PROTEIN; MUCIN 1; P CADHERIN; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CASE STUDY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; NEOPLASMS, BASAL CELL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79251611166     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq227     Document Type: Article

References (35)

1. Widakowich C, de Azabuja E, Gil T. Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol 2007;39:1375-87.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001;98:10869-74.
4. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 2003;100:8418-23.
5. Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S, et al. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clin Cancer Res 2006;12:781-90.
6. Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, et al. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 2010;doi:10.1016/j.compbiomed.2010.01.003.
7. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008;14:8000-9.
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
9. van de Rijn M, Perou CM, Tibshirani R, van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
10. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44.
11. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
12. Tischkowitz M, Brunet J-S, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancer 2007;7:134.
13. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
14. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60.
15. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
16. Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci 2003;100:10393-8.
17. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
18. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
19. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
20. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406-15.
21. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-50.
22. Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score coversion table. Histopathology 2008;53:346-7.
23. Venables WN, Ripley BD. Modern Applied Statistics with S, 4th edn. New York: Springer 2003.
24. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25.
25. Rocha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
26. Stefanini F, Coradini D, Biganzoli E. Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers. BMC Bioinformatics 2009;10:S13.
27. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994;57:498-503.
28. Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Res Treat 2007;105:255-65.
29. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9:R30.
30. Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, et al. P53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-24.
31. Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S. Meta analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic anti-neoplastic drugs. Biochem Biophys Acta 2004;1705:103-20.
32. Harris LN, Broadwater G, Liu NU. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006;8:R66.
33. Wahl AF, Donaldson KL, Fairchild C. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
34. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, et al. P53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007;18:997-1003.
35. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic? J Clin Oncol 2009;27:1153-4.